Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02637687 · ClinicalTrials.gov registry record · Phase 1
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
A Phase 1 study of Solid Tumors Harboring NTRK Fusion, sponsored by Bayer.
- Active
- Registry status
- Phase 1
- Development phase
- 154
- Enrollment target
- 20
- Study locations
NCT02637687 is a Phase 1 study of Solid Tumors Harboring NTRK Fusion that is active but no longer recruiting, run by Bayer. The registered enrollment target is 154 participants. The trial reports 20 study locations across 18 states.
The verdict
NCT02637687, a Phase 1 study of Solid Tumors Harboring NTRK Fusion, is active but no longer recruiting, sponsored by Bayer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 154 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is being done to test the safety of a cancer drug called larotrectinib in children. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer. The first study part (Phase 1) is done to determine what dose level of larotrectinib is safe for children, how the drug is absorbed and changed by their bodies and how well the cancer responds to the drug. The main purpose of the second study part (Phase 2) is to investigate how well and how long different cancer types respond to the treatment with larotrectininb.
Conditions Studied
Interventions
- DRUG Larotrectinib (Vitrakvi, BAY2757556)
Study Locations (20)
California
- Children's Hospital Los Angeles - Hematology/Oncology - Los Angeles
- UCLA Jonsson Comprehensive Cancer Center - Los Angeles
- Lucille Packard Children's Hospital Stanford - Pediatric Nephrology - Palo Alto
Florida
- Nemours Children's Hospital - Florida - Hematology / Oncology - Orlando
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center New York - Main Campus - New York
Ohio
- Cincinnati Children's Hospital Medical Center | Division of Nephrology and Hypertension - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Hematology/Oncology - Philadelphia
Tennessee
- St. Jude Children's Research Hospital - Memphis
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2015-12-16 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02637687
The ClinicalTrials.gov registry entry for NCT02637687 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumors Harboring NTRK Fusion appearing as the primary indexed condition, and to 1 intervention - of which Larotrectinib (Vitrakvi, BAY2757556) is the first listed.
NCT02637687 reports 20 study locations spanning 18 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02637687 about?
NCT02637687 is a clinical study titled "A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children". The study is being done to test the safety of a cancer drug called larotrectinib in children. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer. The first study p...
What is the current status of trial NCT02637687?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 154 participants. The study started on 2015-12-16. Estimated completion is 2026-09-30.
What conditions does trial NCT02637687 study?
This clinical trial studies the following conditions: Solid Tumors Harboring NTRK Fusion.
What interventions are being tested in trial NCT02637687?
The interventions under investigation include: Larotrectinib (Vitrakvi, BAY2757556) (DRUG).
Who is sponsoring clinical trial NCT02637687?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02637687 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors Harboring NTRK Fusion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants
COMPLETED · Phase 1
-
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.